TP, LEO has said on numerous occasions that KEVETRIN has exceeded their expectations on every level in pre-clinical activities. Should this continue, and there is no reason to believe it won't (especially with all the top institutions wanting to trial it), CTIX . . . and we, could be looking at a once-in-a-lifetime "perfect storm" scenario. Let the bidding begin!
